BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 38556452)

  • 1. Peritoneal carcinomatosis in mouse models.
    Arrizabalaga L; Di Trani CA; Risson A; Belsúe V; Gomar C; Ardaiz N; Berrondo P; Aranda F; Bella Á
    Methods Cell Biol; 2024; 185():67-78. PubMed ID: 38556452
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intraperitoneal administration of novel doxorubicin loaded polymeric delivery systems against peritoneal carcinomatosis: experimental study in a murine model of ovarian cancer.
    Colombo PE; Boustta M; Poujol S; Jarlier M; Bressolle F; Teulon I; Ladjemi MZ; Pinguet F; Rouanet P; Vert M
    Gynecol Oncol; 2011 Sep; 122(3):632-40. PubMed ID: 21665252
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intraperitoneal administration of a modified vaccinia virus Ankara confers single-chain interleukin-12 expression to the omentum and achieves immune-mediated efficacy against peritoneal carcinomatosis.
    Bella Á; Arrizabalaga L; Di Trani CA; Gonzalez-Gomariz J; Gomar C; Russo-Cabrera JS; Olivera I; Cirella A; Fernandez-Sendin M; Alvarez M; Teijeira A; Atay C; Medina-Echeverz J; Hinterberger M; Hochrein H; Melero I; Berraondo P; Aranda F
    J Immunother Cancer; 2023 Nov; 11(11):. PubMed ID: 37918917
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intraperitoneal chemotherapy with hydroxycamptothecin reduces peritoneal carcinomatosis: results of an experimental study.
    Li PC; Chen LD; Zheng F; Li Y
    J Cancer Res Clin Oncol; 2008 Jan; 134(1):37-44. PubMed ID: 17665213
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intraoperative and early postoperative chemotherapy into the abdominal cavity using gemcitabine may prevent postoperative occurence of peritoneal carcinomatosis.
    Ridwelski K; Meyer F; Hribaschek A; Kasper U; Lippert H
    J Surg Oncol; 2002 Jan; 79(1):10-6. PubMed ID: 11754372
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Establishment and identification of a rabbit model of peritoneal carcinomatosis from gastric cancer.
    Mei LJ; Yang XJ; Tang L; Hassan AH; Yonemura Y; Li Y
    BMC Cancer; 2010 Apr; 10():124. PubMed ID: 20359350
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel, genetically induced mouse model that recapitulates the histological morphology and immunosuppressive tumor microenvironment of metastatic peritoneal carcinomatosis.
    Tseng SH; Park ST; Lam B; Tsai YC; Cheng MA; Farmer E; Xing D; Hung CF
    J Immunother Cancer; 2020 Feb; 8(1):. PubMed ID: 32111730
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted intraabdominal chemotherapy for peritoneal carcinomatosis.
    Samel S; Löhr M
    Cancer Treat Res; 2007; 134():469-82. PubMed ID: 17633075
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mouse Models of Peritoneal Carcinomatosis to Develop Clinical Applications.
    Bella Á; Di Trani CA; Fernández-Sendin M; Arrizabalaga L; Cirella A; Teijeira Á; Medina-Echeverz J; Melero I; Berraondo P; Aranda F
    Cancers (Basel); 2021 Feb; 13(5):. PubMed ID: 33669017
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting of p32 in peritoneal carcinomatosis with intraperitoneal linTT1 peptide-guided pro-apoptotic nanoparticles.
    Hunt H; Simón-Gracia L; Tobi A; Kotamraju VR; Sharma S; Nigul M; Sugahara KN; Ruoslahti E; Teesalu T
    J Control Release; 2017 Aug; 260():142-153. PubMed ID: 28603028
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of implantation sites for the development of peritoneal metastasis in a colorectal cancer mouse model using non-invasive bioluminescence imaging.
    Taibi A; Albouys J; Jacques J; Perrin ML; Yardin C; Durand Fontanier S; Bardet SM
    PLoS One; 2019; 14(7):e0220360. PubMed ID: 31365553
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Efficacy of 1 384 cases of peritoneal carcinomatosis underwent cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy].
    Yu Y; Li XB; Lin YL; Ma R; Ji ZH; Zhang YB; An SL; Liu G; Yang XJ; Li Y
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Mar; 24(3):230-239. PubMed ID: 34645167
    [No Abstract]   [Full Text] [Related]  

  • 13. Metastatic pattern of CC531 colon carcinoma cells in the abdominal cavity: an experimental model of peritoneal carcinomatosis in rats.
    Lopes Cardozo AM; Gupta A; Koppe MJ; Meijer S; van Leeuwen PA; Beelen RJ; Bleichrodt RP
    Eur J Surg Oncol; 2001 Jun; 27(4):359-63. PubMed ID: 11417980
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual blockade of MET and VEGFR2 signaling pathways as a potential therapeutic maneuver for peritoneal carcinomatosis in scirrhous gastric cancer.
    Kasai S; Kuwayama N; Motoo Y; Kawashima A; Matsumoto K; Yano S; Matsushima K; Yasumoto K
    Biochem Biophys Res Commun; 2022 Apr; 600():80-86. PubMed ID: 35196631
    [TBL] [Abstract][Full Text] [Related]  

  • 15. STING activation normalizes the intraperitoneal vascular-immune microenvironment and suppresses peritoneal carcinomatosis of colon cancer.
    Lee SJ; Yang H; Kim WR; Lee YS; Lee WS; Kong SJ; Lee HJ; Kim JH; Cheon J; Kang B; Chon HJ; Kim C
    J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34145029
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peritoneal tumor carcinomatosis: pharmacological targeting with hyaluronan-based bioconjugates overcomes therapeutic indications of current drugs.
    Montagner IM; Merlo A; Zuccolotto G; Renier D; Campisi M; Pasut G; Zanovello P; Rosato A
    PLoS One; 2014; 9(11):e112240. PubMed ID: 25383653
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of primary colon cancer with peritoneal carcinomatosis: comparison of concomitant vs. delayed management.
    Pestieau SR; Sugarbaker PH
    Dis Colon Rectum; 2000 Oct; 43(10):1341-6; discussion 1347-8. PubMed ID: 11052509
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduction of peritoneal carcinomatosis by intraperitoneal administration of phospholipids in rats.
    Otto J; Jansen PL; Lucas S; Schumpelick V; Jansen M
    BMC Cancer; 2007 Jun; 7():104. PubMed ID: 17584925
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD44-targeting for antitumor drug delivery: a new SN-38-hyaluronan bioconjugate for locoregional treatment of peritoneal carcinomatosis.
    Serafino A; Zonfrillo M; Andreola F; Psaila R; Mercuri L; Moroni N; Renier D; Campisi M; Secchieri C; Pierimarchi P
    Curr Cancer Drug Targets; 2011 Jun; 11(5):572-85. PubMed ID: 21486216
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.